|Day's Range||7.00 - 7.00|
A group of unions and consumer groups wrote to U.S. antitrust enforcers on Tuesday to oppose a proposed remedy that could lead to U.S. approval for AbbVie Inc's planned purchase of Allergan Plc . In its letter to the Federal Trade Commission, which is reviewing the merger to ensure it is legal, the groups argued that a plan for the companies to divest Allergan's brazikumab, which is being developed to treat ulcerative colitis and Crohn's disease, was inadequate to resolve antitrust concerns raised by the planned deal. AbbVie did not immediately respond to a request for comment.
AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
Bob Doll, chief equity strategist at Chicago fund manager Nuveen, says markets are priced for good news. But he also doesn’t expect a recession.
AbbVie's SKYRIZI™ Now Listed on the Nova Scotia Formulary for the Treatment of Moderate to Severe Plaque Psoriasis
A passenger who was repatriated from Wuhan, China, on a U.S. flight and has been in quarantine in San Diego is the latest individual in the U.S. to test positive for the coronavirus, according to media reports.
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25. Michael Severino, M.D., vice chairman and president and Robert A. Michael, executive vice president and chief financial officer, will present at 9:30 a.m. Central time.
Allergan stock jumped Monday after the Botox-making pharma company topped fourth-quarter expectations ahead of its $63 billion acquisition by AbbVie. Botox sales edged up in the quarter.